Novartis's shift into high-tech drugs won praise for providing patients wit...
FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo
Shareholders at the event in Basel also approved Novartis’s planned spin-off of its Alcon eyecare unit, due for coming months, with investors with five Novartis shares due to receive one share of Alcon stock. Chief Executive Vas Narasimhan, who did not testify this week before the U.S. Senate with other global drug industry executives also facing criticism for drug prices, said he seeks to price medicines based on their value, adding Novartis needs a fair return to further research and development.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pharmaceutical Industry CEOs Face Senate Hearing on Drug PricesExecutives for some of the biggest drug companies will visit Capitol Hill on Tuesday to face tough questions in a Senate hearing on the rising cost of medicines.
Read more »
Pharmaceutical Company CEOs Face Grilling in Senate Over High Drug PricesLawmakers criticized pharmaceutical industry leaders during Senate testimony Tuesday, for failing to put patients before profits. The executives deflected blame over high drug prices to insurance companies and middlemen.
Read more »
Fed Chairman Heads to Capitol, Faces Questions on Slowing Economy, Trump CriticismWhen Jerome Powell heads to Capitol Hill for two days of hearings, he will face an economic and political backdrop greatly changed from when he gave his congressional testimony in July.
Read more »
Don't expect the Trump administration's newest drug pricing plan to lower all US drug prices yet, 7 pharma execs just told CongressSeven top pharma executives said they were in support of lowering drug prices. But they also had certain conditions.
Read more »
Pharma companies wants the government to do something about high drug prices, so long as it's not forcing them to lower their drug pricesPharmaceutical executives seemed to reach a consensus that it'll take government action to solve the conundrum of how we get to lower drug prices.
Read more »
Hearings on 'sky-high' drug prices show how little has changed in 60 yearsThe subjects likely to surface at Tuesday's Senate hearings -- high drug prices and profits, limited price transparency, aggressive marketing, alleged patent abuse and mediocre, 'me-too' drugs -- are identical to the issues senators investigated decades ago.
Read more »
Drugmakers’ CEOs clash with senators in hearing on drug price hikesExecutives from seven pharmaceutical giants endure grillings but also push back Tuesday on Capitol Hill, as they testify before the Senate Finance Committee about rising drug prices.
Read more »
In Senate testimony, pharma executive admits drug prices hit poor the hardestTop execs from 7 major pharmaceutical companies told a Senate committee that they could not commit to lower the price of commonly used prescription drugs even as they admitted that they control those prices.
Read more »